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OBJECTIVE—The goals of this study were to examine trajectories of blood pressure (BP) in
adults with diabetes and investigate the association of trajectory patterns with mortality.
RESEARCH DESIGN AND METHODS—A nonconcurrent longitudinal design was
used to monitor 3,766 Medicare patients with diabetes from 2005 through 2008. Data were ex-
tracted from a registry of Medicare beneﬁciaries, which was developed by a large academic
practicethatparticipatedinthePhysicianGroupPracticeMedicareDemonstration.Therelation-
ship between BP trajectories and all-cause mortality was modeled using multilevel mixed-effects
linear regression.
RESULTS—During the 4-year study period, 10.7% of the patients died, half of whom were
aged $75 years. The crude and adjusted models both showed a greater decline in systolic and
diastolic BP in patients who died than in those who did not die. In a model adjusted for age, sex,
race, medications, and comorbidities, the mean systolic BP decreased by 3.2 mmHg/year (P ,
0.001)intheyearsbeforedeathandby0.7mmHg/year(P,0.001)inthosewhodidnotdie(P,
0.001 for the difference in slopes). Similarly, diastolic BP declined by 1.3 mmHg/year for those
who died (P , 0.001) and by 0.6 mmHg/year for those who did not die (P , 0.001); the
difference in slopes was signiﬁcant (P = 0.021).
CONCLUSIONS—Systolic and diastolic BP both declined more rapidly in the 4 years before
death than in patients who remained alive.
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B
lood pressure (BP) is usuallyrecorded
at every visit to the physician, yet
patterns of BP over time in popula-
tions are not often published. BP trajec-
tories have been reported in longitudinal
studies of children (1,2), but trajectories
in adults with diabetes are usually ancil-
lary to treatment trials for hypertension,
and the results are explained in terms of
the assigned medication (3,4). In healthy
adults evaluated longitudinally, systolic
BP is relatively stableuntilapproximately
age 50, after which there is a steady in-
creasewithage(5).DiastolicBPincreases
longitudinally with age in healthy adult
men,butinwomen,itincreasesinmiddle
age and declines slightly after age 70 (5).
In the Framingham population, systolic
BP increased from age 30 through 84 but
diastolic BP increased in middle age (40–
60 years) and then declined afterward
(6). This follows a similar pattern to that
reported with cross-sectional data from
the National Health and Nutrition Exam-
ination Study (7,8).In theGöteberg pop-
ulation,systolicBP increaseduntilage75
and decreased between 75 and 79 in those
without antihypertensive therapy, whereas
diastolic BP increased during middle age
and then decreased after age 75 (9).
Missing from the medical literature are
longitudinal BP trajectories in populations
with diabetes. In particular, BP trajectories
before death have yet to be reported.
Therefore, we investigated patterns of
BP over time in a longitudinal study of
Medicare patients within a diabetes registry.
RESEARCH DESIGN AND
METHODS
Type of study
We conducted a nonconcurrent longitu-
dinal study using secondary data analysis
of electronic medical record information
linked to Medicare claims.
Study population
We studied 3,766 Medicare beneﬁciaries
with diabetes, attributed by the Centers
for Medicare & Medicaid Services (CMS)
to the University of Michigan Faculty
Group Practice based on their participa-
tioninthePhysicianGroupPracticeDem-
onstration (10), who were entered into
the University of Michigan diabetes regis-
try from 2005 through 2008. Patients in
the diabetes registry are adults (aged $18
years) who have met the following three
criteria:
1) have a diagnosis of diabetes in the
Problem Summary List or a diagnosis
of diabetes in the past 3 years with at
least two face-to-face encounters in an
ambulatorycaresettingoroneface-to-
face encounter in an acute care setting
such as the emergency department;
2) have received antihyperglycemic med-
ication,diabeticsupplies(strips/lancets/
glucometer), have a HbA1c .6.4% or
twoormoreglucoseresults$200mg/dL;
and
3) wereseenbyaprimarycarephysician,
geriatric, or an endocrinology spe-
cialistatleasttwiceinthepast2 years,
withoneofthosevisitsinthepast395
days.
Data
CMS provided complete claims data
each year for the beneﬁciaries assigned
to the Physician Group Practice Demon-
stration project. National Claims History
ﬁles contained information on beneﬁ-
ciary diagnoses, utilization of services,
and Medicare payments made to providers
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ORIGINAL ARTICLEfortheseservices.Medicareenrollmentdata
included age, sex, and geographic informa-
tion.
The diabetes registry is a central re-
pository for clinical data from various
systems related to disease management
and preventive care services. During the
study period, registry information was
updated between every day and monthly
(varying by data element), and patient-
centeredsummaryreportswereproduced
every 6 months. Eight reporting cycles
occurred from 2005 through 2008, two
for each of the 4 years. Accordingly,
patients in the study may have had as
many as eight BP reports. To study trends
longitudinally, patients must have had at
least two reports to be included in this
study cohort.
Variables and their measurement
Data used for this analysis included age,
sex, race, Medicaid insurance, height and
weight,medications(statins,insulin,ACE
inhibitors, angiotensin receptor blockers
[ARB]), and the most recent HbA1c and
LDL cholesterol levels. BMI was calcu-
lated from height and weight. Death
was determined from the Medicare en-
rollment ﬁle and themedicalrecords. Co-
morbidities were obtained from Medicare
claims, and included speciﬁcd i s e a s e s
aswellastheannualMedicareassignment
of Hierarchical Condition Categories
(HCCs), which were used to derive the
overall burden of disease (i.e., severity
scores) (11). Individual comorbid condi-
tions included congestive heart failure
(CHF), renal failure or dialysis, severe
malignancies (digestive tract, lung, and
other severe cancers; acute leukemia;
metastatic cancer), liver disease (end-
stage liver disease, cirrhosis of the liver,
or chronic hepatitis), and stroke (cerebral
hemorrhage, ischemic or unspeciﬁed
stroke, or hemiplegia/hemiparesis).
The BP measurements included in this
studywerethelastBPrecordedwithineach
of the 6-month reporting periods. BP mea-
surements during hospitalization or emer-
gency department visits were excluded.
For each patient, BP was determined by
usual clinical practice during the outpa-
tientofﬁcevisit.Therefore,theprocedure
for measuring BP was similar to that used
for clinical decision making at the point
ofcareandwasbasedonindividualclinic
processesandthejudgmentoftheproviders.
Analytic strategy
The participants represented a ﬂuid co-
hort because various patients entered
and/or left the study at various calendar
times during the 4-year period. BP was
recorded in 1,195 of the 3,766 subjects
(32%) at each 6-month period during the
course of the entire 4-year study (i.e.,
eight recorded BPs); BP was recorded at
two periods for 410 (11%), with the
remaining subjects observed for three to
seven periods. To ensure that we were
comparing a similar period before death
forthepatientswhodied,theBPsrecorded
beforedeathwerealigned(i.e.,right-justiﬁed);
thus, BP trajectories reﬂected the series of
last BPs recorded before death. The main
results are presented as right-justiﬁed for
all patients, and sensitivity analyses were
conducted using left-justiﬁcation (i.e., BPs
recorded as the patients entered the
cohort).
Multilevelmixed-effectslinearregres-
sionwas theprincipal methodofanalysis.
The likelihood ratio test for nested mod-
els was used to assess the signiﬁcance
of random intercepts and random coef-
ﬁcients (i.e., slopes). Trajectories were
calculated using the ﬁxed-portion linear
predictor plus the contribution deter-
mined by the predicted random effects.
An interaction term was used to evaluate
signiﬁcant differences in slopes between
different subgroups. Age of the patient at
the time of the report, ACE inhibitors or
ARB drugs, statins, insulin, values of
HbA1c and LDL cholesterol, BMI, and
Table 1—Characteristics of patients with diabetes at baseline and mortality during
the study period
Variables All subjects Mortality P
Age (years)
,65 1,215 (32.3) 96 (7.9)
65–69 745 (19.8) 48 (6.4)
70–74 679 (18.0) 57 (8.4)
.75 1,127 (29.9) 203 (18.0) ,0.001
Sex
Male 1,747 (46.4) 212 (12.1)
Female 2,019 (53.6) 192 (9.5) 0.009
Race
White 3,026 (80.4) 335 (11.1)
African American 482 (12.8) 47 (9.8)
Other 258 (6.8) 22 (8.5) 0.340
Payer
Medicaid* 714 (19.0) 79 (11.1)
Other 3,052 (81.0) 325 (10.6) 0.747
ACE/ARB therapy
Yes 2,572 (68.3) 264 (10.3)
No 1,194 (31.7) 140 (11.7) 0.178
Statin therapy
Yes 2,473 (65.7) 241 (9.7)
No 1,293 (34.3) 163 (12.6) 0.007
CHF
Yes 753 (20.0) 179 (23.8)
No 3,013 (80.0) 225 (7.5) ,0.001
Dialysis or renal failure
Yes 639 (17.0) 169 (26.4)
No 3,127 (83.0) 235 (7.5) ,0.001
Stroke or hemiplegia
Yes 246 (6.5) 53 (21.5)
No 3,520 (93.5) 351 (10.0) ,0.001
Liver disease
Yes 73 (1.9) 23 (31.5)
No 3,693 (98.1) 381 (10.3) ,0.001
Metastatic cancer
Yes 117 (3.1) 39 (33.3)
No 3,649 (96.9) 365 (10.0) ,0.001
Data are presented as n (%). *Medicaid dually eligible and Medicaid only.
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Rogers and Associatesdisease severity score (HCC) were treated
as time-varying covariates in the ﬁnal re-
gression models. The a was set at 0.05
(two-tailed).
Some data were missing on various
6-month reports for HbA1c (5%), LDL
cholesterol (16%), HCC score (22%),
BMI (23%), and insulin (35%) during
the course of the 4-year study. Because
this was a large group, we chose not to
impute values. Rather, we conducted a
sensitivity analysis that included these
additional variables in a fully adjusted
regression model.
This study was approved by the Uni-
versity of Michigan IRB and conducted
under a Data Use Agreement with CMS.
RESULTS—In this cohort, 32% of pa-
tients were aged ,65 and 30% were $75
yearsatthetimeoftheinitialvisit(Table1).
Women accounted for 54% of subjects,
and 80% of the patients were white. At
the time of entry into the study, 68% of
patients were receiving ACE/ARB therapy,
and66%werereceivingstatinmedications.
Therewere404patients(10.7%)whodied,
half of whom were aged $75 years at the
initial visit. Increasing age and male sex
were risk factors for death, whereas statin
therapywasprotective.CHF,dialysisor
renal failure, stroke, liver disease, and
malignancy were signiﬁcant predictors of
death.
Systolic and diastolic BP both signif-
icantly declined before death in patients
with diabetes. In an unadjusted model,
mean systolic BP declined 3.1 mmHg
(95% CI 1.9–4.3) and mean diastolic BP
declined 1.6 mmHg (0.9–2.3) annually
before death. In the adjusted model
(Table 2), systolic pressure decreased by
3.2mmHg/year(P , 0.001)inthosewho
died and by 0.7 mmHg/year (P , 0.001)
in those who did not die (P , 0.001 for
the difference in slopes between trajecto-
ries). Diastolic pressure declined by 1.3
mmHg/year for those who died (P ,
0.001) and by 0.6 mmHg/year for those
who did not die (P , 0.001); the differ-
ence in slopes remained signiﬁcant (P =
0.021). The addition of a quadratic term
to detect a nonlinear change in slope was
not signiﬁcant for systolic (P = 0.965) or
diastolic BP (P = 0.761) in the adjusted
models. BP trajectories generated from the
adjusted models are shown in Fig. 1 and
Fig. 2, with stratiﬁcation by mortality.
In the fully adjusted model, mean
systolic BP signiﬁcantly increased with
age (0.23 mmHg for each year; P ,
0.001), female sex (1.57 mmHg; P =
0.004), African American race (3.14
mmHg; P , 0.001), BMI (0.11 mmHg
for each kg/m
2 increase; P = 0.001), and
for those with renal failure or receiving
dialysis (5.08 mmHg; P , 0.001). Mean
systolic BP signiﬁcantly decreased with
Medicaid insurance (22.05 mmHg; P =
0.006) and in those with CHF (24.03
mmHg; P , 0.001). Mean diastolic BP
signiﬁcantly increased with African
American race (2.58 mmHg; P , 0.001)
and BMI (0.07 mmHg; P = 0.001). Mean
diastolic BP signiﬁcantly decreased with
age (20.19 mmHg; P , 0.001), female
sex (21.09 mmHg; P = 0.001), and in
those with CHF (21.27 mmHg; P =
0.003). Some of these ﬁndings are illus-
trated in Fig. 1 and Fig. 2; the increased
systolic BP with older age can be seen by
the shift in the BP trajectories on the
y-axis. Systolic BP is greater in older
patients, whereas diastolic BP is lower in
older patients. Women have higher sys-
tolic but lower diastolic BP than men.
In secondary analyses, the addition of
HbA1c,LDLcholesterol,BMI,insulin,and
severity risk score did not substantially
change the major ﬁndings (Table 2, fully
adjustedmodel).ThedeclineinsystolicBP
was particularly evident (26.2 mmHg/
year) in those who died. We also evaluated
potential differences in the slope of BP tra-
jectories for those with and without CHF
(regardless of mortality); the interaction
term was not signiﬁcant for systolic BP
(P = 0.951) or diastolic BP (P = 0.056).
Similarly, there was no effect modiﬁcation
by younger age (,65 years) versus older
age ($65 years); the interaction terms
for differences inslope were not signiﬁcant
for systolic (P = 0.184) or diastolic BP (P =
0.979).
We repeated the statistical analyses
using left-justiﬁcation of the BP measure-
ments; the results did not appreciably
change. The rate of decline of BP was
greater in those patients who died than in
patients who remained alive (P , 0.001
forsystolicBP;P =0.013fordiastolicBP).
Systolic BP decreased by 2.7 mmHg/year
(95% CI 1.7–3.7) and diastolic BP de-
creased by 1.5 mmHg/year (95% CI
0.9–2.1) in those who died. Systolic BP
declined by 0.7 mmHg/year (95% CI
0.5–0.9) and diastolic BP declined by
0.7 (95% CI 0.6–0.9) in the patients
who remained alive.
Of the 404 patients who died, 62
(15%) died between the last clinic visit
and the end of the reporting period, 86
(21%) died within 8 weeks of the last
reporting period, 158 (39%) died within
8t o24wee kso fth el as tr ep ort ingpe ri o d,
and 98 (24%) died .24 weeks from the
last reporting period.
CONCLUSIONS—Mean systolic and
diastolic BP both declined in the years
before death in patients with diabetes.
This annual rate of decline was signiﬁ-
cantly more marked (23.2 mmHg sys-
tolic and 21.3 mmHg diastolic) than in
thepatientswhoremainedalive.Moreover,
the decline was evident after adjustment
Table 2—Annual mean change in BP in patients with diabetes, by mortality
Group
Patients
n
Annualchange
in BP (mmHg) 95% CI P interaction
Systolic BP
Adjusted model:*
Alive 3,362 20.7 20.4 to 20.9
Died 404 23.2 22.2 to 24.2 ,0.001
Fully adjusted model†
Alive 2,251 20.5 20.02 to 21.1
Died 169 26.2 23.0 to 29.4 0.001
Diastolic BP
Adjusted model*
Alive 3,362 20.6 20.5 to 20.7
Died 404 21.3 20.7 to 21.9 0.021
Fully adjusted model†
Alive 2,251 20.4 20.05 to 20.7
Died 169 23.4 21.5 to 25.3 0.002
*Adjusted for age, sex, race, Medicaid, ACE inhibitors or ARBs, statins, congestive heart failure, dialysis or
renalfailure,malignancies,liverdisease,andstroke.†Adjustedforage,sex,race,Medicaid,ACEinhibitorsor
ARBs,statins,congestiveheartfailure,dialysisorrenalfailure,malignancies,liverdisease,stroke,BMI,HbA1c,
LDL cholesterol, insulin, and disease severity score (HCC).
1536 DIABETES CARE, VOLUME 34, JULY 2011 care.diabetesjournals.org
Blood pressure trajectories prior to deathformajororganfailure—heart,kidney,and
liver—as well as for common causes of
death such as malignancies and stroke.
These ﬁndings may signal an underlying
populationofvulnerablepatients,although
it is unclear whether the BP decline is
merely a symptom of this vulnerability or
isoneofseveralphysiologiccontributorsto
the dying process.
The rate of change in BP has been of
lesser signiﬁcance than threshold values
that serve as guides to initiation or adher-
ence to antihypertensive therapy (12).
Studies of outcomes in those who experi-
ence signiﬁcant changes (either increases
or decreases) in BP would be appropriate.
Although hypertension in middle age is a
riskfactorfordeath,itisnotclearwhether
there is a point at which therapy should
be re-evaluated in the very old or in those
withamarkedrateofBPdecline.Asimilar
phenomenon has been found in cohorts
evaluated for the incidence of dementia:
elevated BP in earlier life increases the
risk, but a decline in BP is evident in the
5 years just before diagnosis (13).
There are few studies that plot the
trajectories of BP in patients with diabe-
tes. Maddox et al. (14) plotted BP trajec-
tories over time in patients with diabetes
and/or chronic kidney disease who were
newly diagnosed with coronary artery
disease. Their results indicated that good
control of BP decreased the risk of myo-
cardial infarction and the risk of revascu-
larization, although overall mortality did
not improve.
There is some corroborating evidence
for our ﬁndings. Analysis of a cohort
m o n i t o r e df o ram e d i a no f9 . 8y e a r s
showed the risk of death in patients with
type 2 diabetes increased by 15% for every
10-mmHg decrease in systolic BP and in-
creased by 22% for every 10-mmHg de-
crease in diastolic BP (15). This inverse
relationship was particularly evident in
the oldest age group. Similarly, Rönnback
et al. (16) reported that low systolic and
diastolic BP predicted elevated all-cause
and cardiovascular deaths in patients with
type 2 diabetes during a median follow-up
of 9.5 years.
TheActiontoControlCardiovascular
Risk in Diabetes (ACCORD) trial demon-
strated that intensive hypertensive ther-
apy did not reduce mortality in patients
with type 2 diabetes; the hazard ratio for
intensive versus standard BP therapy was
1.07 (95% CI 0.85–1.35) for all-cause
mortality (3). Likewise, Cooper-DeHoff
et al. (17) found that tight control of sys-
tolic BP in patients with diabetes and cor-
onary artery disease did not improve
mortality. The hazard ratio for all-cause
mortality was 1.20 (95% CI 0.99–1.45);
again, suggesting a nonsigniﬁcant ex-
cess of deaths in patients with tight BP
control compared with those receiving
usual care. They also showed that sys-
tolic BP of ,110 mmHg was associated
with an increase in all-cause mortality
compared with systolic BP of 125 to 130
mmHg.
The UK Prospective Diabetes Study
Group found that tight BP control re-
duced diabetes-related deaths by 32%
without a signiﬁcant reduction in all-
cause mortality after a median follow-up
of 8.4 years (18). However, the Appropri-
ate Blood Pressure Control in Diabetes
(ABCD) trial demonstrated a decrease in
all-cause mortality (P = 0.037) for inten-
sive versus moderate BP therapy in pa-
tients with type 2 diabetes during a
period of 5.3 years, despite showing no
statisticallysigniﬁcantdifferencesinmyo-
cardial infarction, cerebrovascular, or
congestive heart failure events (19).
Figure 1—Mean systolic and diastolic BP trajectories for patients with diabetes mellitus, by age
and mortality.
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Rogers and AssociatesPrevious authors have noted a con-
cern regarding aggressive treatment in
older patients (20,21). A meta-analysis
of randomized controlled trials showed
treatment of hypertension did not
yield a signiﬁcant reduction in all-cause
mortality in patients aged $80 years
(20). Moreover, a nonsigniﬁcant relative
excess of all-cause death was noted in
those who received antihypertensive
treatment. However,only 14%ofthe par-
ticipants had a history of diabetes. Bulpitt
et al. (21) reported similar ﬁndings in an
open pilot trial of patients aged $80
years, although the proportion with dia-
beteswasnotstated.Incontrast,antihyper-
tensive treatment in mostly nondiabetic
individuals aged $80 years aimed to a BP
target of 150/80 mmHg signiﬁcantly re-
duced the rate of death from any cause by
21% (22).
Our investigation did not determine
the reason for the declining BP before
death, and therefore, we advise caution
in the interpretation. We have little evi-
dence to indicate whether treatment
intensiﬁcation played a role or whether
declining BP is a harbinger of the dying
process in certain patients. Our results
suggest that the decrease in BP is not
merely due to the presence of CHF or
increased age. It is important to recognize
that the decline was observed in the mean
pressures in a population and was not
observed in all individuals. Because this
was a registry-based study, the ﬁndings
shouldbeinvestigatedinalarge,population-
based cohort of patients with diabetes. It is
unclear whether declining BP could be a
reliable predictor of mortality or whether
the patients in this registry differ from the
overall population in ways that this investi-
gation did not capture.
Inconclusion, itmaybeusefultoplot
BPs over time in populations, similar to
what many physicians do for individual
patients with diabetes. The trajectory of
BP leading up to death can be revealing.
Our results suggest that a signiﬁcant de-
cline occurs in both systolic and diastolic
BP several years before death in popula-
tions of patients with diabetes.
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